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Abstract
High-risk human papillomavirus (HPV) E6 and E7 oncoproteins are essential factors for HPV-induced carcinogenesis, 
and for the maintenance of the consequent neoplastic growth. Cellular transformation is achieved by complex 
interaction of these oncogenes with several cellular factors of cell cycle regulation including p53, Rb, cyclin-CDK 
complexes, p21 and p27. Both persistent infection with high-risk HPV genotypes and immune dysregulation are 
associated with increased risk of HPV-induced squamous cell carcinoma.
Introduction
Cancer is a disease primarily caused by cytogenetic
changes that progress through a series of sequential
somatic mutations in specific genes resulting in uncon-
trolled cellular proliferation [1,2]. It may be caused by
exposure to any one or more of a variety of chemical or
physical agents, by random errors of genetic replication,
or by errors in DNA repair processes. Almost all cancers
follow carcinogenic events in a single cell (are monoclo-
nal in origin), and this characteristic distinguishes neo-
plasms from hyperplasias that have a polyclonal origin
[1].
Mutations in genes controlling cell cycle progression
(gatekeeper genes) and DNA repair pathways (caretaker
genes) are the essential initiating events of cancer. Both
oncogenes and tumour suppressor genes act as gate-
keeper genes. After mutation, certain genes may acquire
new functions that lead to increased cell proliferation:
these genes are called oncogenes. Such a mutational
event occurs characteristically in a single allele of the
future oncogene, and that allele then directly causes dys-
regulation of molecular mechanisms that control cell
cycle progression. Tumour suppressor genes on the other
hand, lose their function when both alleles are inacti-
vated, and consequently lose their capacity to inhibit cell
proliferation [1-7].
Caretaker genes are DNA repair-genes that serve to
maintain the integrity and stability of the genome. Muta-
tions in these genes do not directly contribute to uncon-
trolled cell proliferation, but increase the likelihood of
mutations in the gatekeeper genes and may thus indi-
rectly promote malignant cellular transformation
[1,4,5,7].
Epigenetic modification refers to changes in gene
expression (phenotype) without alteration in DNA struc-
ture (genotype). Somatic alterations of specific genes
together with epigenetic events determine the develop-
ment of malignancy. Significant among the epigenetic
events are methylation of cytosine bases of DNA and
modification of histones by acetylation or methylation
which are associated with silencing of tumour suppressor
genes [1-3,8-11].
Carcinogenesis can be seen as a Darwinian process
involving sequential mutations giving the mutated cells
growth dominance over the normal neighbouring cells
resulting in the increased representation of the mutated
cells in the affected tissue [12-15]. It is generally assumed
that five to ten mutational events in as many different
genes will transform a normal cell into a malignant phe-
notype [1,2].
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bio-pathological processes of carcinogenesis of the ano-
genital region has been extensively researched and docu-
mented, and therefore Part 1 of this review is
substantially based on this material. These bio-pathologi-
cal sequential events are described in some detail as a
basis for a discussion in Part 2 of the role of HPV in the
pathogenesis of oral and oropharyngeal squamous cell
carcinoma.
Human papillomavirus (HPV)-induced 
carcinogenesis
High-risk HPV E6 and E7 oncoproteins expressed in epi-
thelial cells infected with HPV are implicated in the
increased proliferation and in the abnormal differentia-
tion of these cells [16,17]. When the E6/E7 proteins are
the expression of infection of the cell with low-risk HPV,
then these active proteins may induce benign neoplasms.
However, when E6/E7 proteins are the expression of
high-risk HPV infection, they subserve the role of onco-
proteins and they have the capacity to induce dysplastic
and malignant epithelial lesions [18,19].
The association between cancer of the uterine cervix
and high-risk HPV infection is well established. It is evi-
dent that HPV is an essential agent, but is not by itself
sufficient to induce squamous cell carcinoma of the cer-
vix. HPV DNA is found in more than 99% of biopsy spec-
imens of squamous cell carcinoma of the cervix. In more
than 70% of these HPV DNA positive biopsy specimens,
the DNA is of high-risk HPV-16 and HPV-18 origin [20].
The prevalence of HPV infection of the cervix of the
uterus is high, but in these same subjects the incidence of
squamous cell carcinoma of the cervix is relatively low
[21]. Therefore, besides persistence of the HPV infection,
the HPV genotype, infection with multiple HPV geno-
types, whether the viral DNA is present episomally or
integrated and the quantum of cellular viral load may be
important factors in the development of the cancer.
Equally important may be other co-factors that may vary
from individual to individual but can include immune fit-
ness, nutritional status, the use of tobacco, and co-infec-
tion with other sexually transmitted agents including HIV
and herpes simplex virus [20].
E6 and E7 oncoproteins can inactivate the genetic
mechanisms that control both the cell cycle and apoptosis
[16,17]. The hallmark of high-risk HPV E6 oncogenic
activity is degradation of the p53 tumour-suppressor
gene. The functions of p53 in the cell cycle include con-
trolling the G1 transition to the S phase of the cell cycle at
the G1 checkpoint by inducing expression of cyclin inhib-
itors p16, p21 and p27 that block the activities of cyclin-
CDKs (cyclin-dependant kinase) complexes, thus mediat-
ing arrest of the cell cycle by blocking the progression of
the cell cycle at the G1/S transition [17].
p53 activities mediate cell proliferation in response to
mitogenic stimulation; mediate arrest of the cell cycle
growth at the G1 checkpoint following DNA damage,
hence permitting repair of the damaged DNA before the
cell enters the DNA synthesis phase; and mediate induc-
tion of apoptosis of cells in which the DNA damage is
beyond repair [22,23]. Therefore, inactivation, degrada-
tion, or mutation of the p53 gene may dysregulate its
functions resulting in increased cell proliferation, in accu-
mulation of damaged DNA, in growth of cells harbouring
DNA errors, and in prolonged cell survival. However, loss
of p53 function alone is not sufficient for the develop-
ment of cancer, and other cytogenetic alterations are
required for complete malignant transformation [22,23].
In addition to these properties, E6 oncoprotein of high-
risk HPV types can also mediate cell proliferation
through the PDZ-ligand domain [16]. The PDZ domain is
located at areas of cell-to-cell contact, such as tight junc-
tions of epithelial cells, and is associated with signal
transduction pathways. The binding of high-risk HPV E6
oncoprotein to the PDZ family of proteins may result in
degradation of the PDZ domain [24,25] leading to dysreg-
ulation of organization, differentiation, and of the chro-
mosomal integrity of HPV infected epithelial cells [18].
This may contribute to morphological transformation of
keratinocytes infected with high-risk HPV [26] and to
induction of epithelial hyperplasia [27].
Telomerase is an enzyme that adds hexanucleotide
repeats onto the end of the chromosome telomere [3].
Telomerase activity is usually restricted to embryonic
cells and is absent in normal somatic cells [25]. When
telomerase is absent, there is progressive shortening of
telomeres as the cells repetitively divide, ultimately
resulting in senescence of these cells [3,25,28]. HPV-
induced activation of telomerase prevents the shortening
of telomeres resulting in prolongation of the lifespan of
HPV-infected cells [24,25,28].
High risk HPV E7 oncoprotein has the capacity to initi-
ate DNA synthesis in differentiated epithelial cells mainly
by binding and inactivating the Rb apoptosis/tumour-
suppressor gene. The Rb family of proteins plays an
essential role in controlling the cell cycle by governing the
checkpoint between the G1 and the S phase. Hypophos-
phorylated Rb binds to E2F transcription factor forming a
Rb-E2F complex, making E2F unavailable for transcrip-
tion of genes associated with DNA synthesis. Upon phos-
phorylation of Rb by cyclin-CDK complexes, E2F is
released from the Rb-E2F transcription repressor com-
plex, and it induces transcription of the S-phase genes
[16,18,23,25,29].
E7 oncoprotein of high-risk HPV types functionally
inactivates the Rb family of proteins resulting in overex-
pression of E2F transcription factor with upregulation of
cell cycle genes resulting in DNA replication, in the tran-
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increased cell proliferation [16,18,25].
E7 oncoprotein can also interact with other cellular fac-
tors that control the cell cycle including histone deacety-
lases, AP-1 transcription complex and CDK inhibitors,
p21 and p27 [16]. Furthermore, E7 of high-risk HPV-16
and -18 can decrease the expression of major histocom-
patibility complex (MHC) class I molecules, thus interfer-
ing with MHC class I antigen presentation, resulting in
downregulation of cellular immune responses, allowing
HPV to persist in infected epithelial cells [17].
In addition to these properties, high-risk HPV E7 onco-
protein can induce chromosome duplication errors lead-
ing to dysregulation of mitotic spindle formation and
function, contributing to the genomic instability of the
cell [30].
The separate pathological effects of high-risk HPV E6
and E7 on the cell cycle complement each other, and
together E6 and E7 mediate the HPV-associated epithelial
cell transformation, and promote cellular genomic insta-
bility that predisposes the infected cells to full malignant
transformation. High-risk HPV E7 activates the DNA
synthesis and cell replication mechanisms that are nor-
mally inactive in matured epithelial cells, thus initiating
pathological cell growth. By inducing cell survival and
delayed apoptosis of cells with DNA damage, E6 allows
E7 to exert and sustain its pathological effect [18].
Typically, infected epithelial cells of HPV-associated
benign lesions harbour low-risk HPV episomally in the
nuclei. In HPV-associated malignancies, high-risk HPV
DNA may either be integrated within the cellular
genome, or it may be maintained as an episome in the
nuclei of the malignant cells [31]. It is unclear how the
HPV genome, whether episomal within the nucleus or
integrated into the nuclear cellular genome, brings about
the same end result of malignancy [32].
The integration of HPV DNA favours the inactivation
of tumour suppressor genes, p53 and Rb, contributing to
increased cellular chromosomal instability, and prolong-
ing the lifespan of the cell, essential steps in the multi-
step process of HPV-associated carcinogenesis
[11,25,28,33]. It is probable that following the initial
HPV-induced cellular transformation, additional interac-
tions with chemical carcinogens will provide the neces-
sary additional impetus for the development of frank
malignancy (Figure 1) [32].
The integration of the HPV genome as opposed to the
presence of HPV episomally is associated with a greater
frequency of cervical intraepithelial neoplasia (CIN)
grade 3, and with invasive squamous cell carcinoma of
the uterine cervix [11,28,34]. The pathological signifi-
cance of integration is not entirely clear since HPV often
exists concurrently in both episomal and integrated
forms. The chromosomal locations of integrated HPV are
very variable, and there is a paucity of data on the fre-
quencies and chromosomal locations of different HPV
genotypes [11,35].
HPV oncoproteins can act synergistically with intra-
nuclear proto-oncogenes, with cytokines that bind and
activate E6/E7 promoter, with exogenous factors includ-
ing carcinogens in tobacco and dietary agents, steroids,
and UV and X-radiation, to promote HPV-tumourigene-
sis (Figure 1) [31].
Genetic and epigenetic events associated with HPV 
infection
The cellular genomic integrity is maintained by various
caretaker cellular systems, including DNA monitoring
and repair enzymes, checkpoints that regulate the cell
cycle, and genes that ensure the accurate chromosomal
replication during mitosis. Malfunction of cellular care-
taker systems brings about genomic instability that is
associated with increased risk of acquiring accumulative
genetic alterations that can ultimately culminate in car-
cinogenesis. The genomic instability brought about by
HPV-induced malfunction of p53 tumour suppressor
gene results in the inheritance of abnormal DNA by cells
that are not only proliferating in increased numbers, but
surviving longer with consequently increased chances of
malignant transformation [3].
Tumours destined to become malignant appear to be
characterized by chromosomal imbalances, in terms of
gains or losses of genetic material [36]. Most chromo-
somal imbalances affect large genomic regions containing
multiple genes, and have functional consequences that
are unknown. Gains or losses of genetic material lead to
changes in DNA copy-numbers [37]. Genomic gain may
arise from DNA sequence amplification leading to over-
expression of oncogene products; and genomic losses
may be brought about by single-gene or intragenic dele-
tion leading to the loss of the functional product of a
tumour suppressor gene [1,36].
Large-scale genomic gains or losses affecting multiple
genes are frequently observed in cancers and manifest in
changes in DNA copy-numbers, but the identification of
the specific gained or lost gene that promotes the car-
cinogenesis is difficult, and in most cases impossible [36].
HPV-related anal intraepithelial neoplasia is associated
with DNA copy-number abnormalities, and the severity
of the lesion is directly related to the magnitude of the
DNA copy-number changes [33].
In HPV-induced malignancies there are two distinct
epigenetic events. The first is methylation of viral genes
that are associated with increasing viral oncogenic capac-
ity, and the second is silencing of cellular tumour-sup-
pressor genes through hypermethylation of the promoter
regions [11]. Given enough time, the accumulation of epi-
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Figure 1 Flow chart of high-risk HPV pathogenesis of squamous cell carcinoma. By inactivation of p53, high-risk HPV E6 oncoprotein induces 
cell survival and delayed apoptosis, and HPV E7 oncoprotein through inactivation of Rb gene stimulates cellular DNA synthesis and pathological cell 
growth. The separate pathological activities of HPV E6 and E7 on the cell cycle complement each other and mediate the HPV-associated epithelial cell 
transformation.
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nant transformation [33].
Conclusions
As is the case in many other malignancies, HPV-induced
carcinogenesis is a complex process characterized by
alterations in genes encoding tumour-suppressor genes
and by epigenetic modifications. The hallmark of HPV-
induced carcinogenesis is inactivation of p53 tumour-
suppressor gene by the E6 and of Rb apoptosis/tumour
suppressor gene by E7 oncoproteins of high-risk HPV
genotypes. The aberrant function of these genes and the
consequent genomic instability compounded by the addi-
tive effects of one or more cofactors leads to preferential
growth of the affected cells which characterize the pro-
gressive uncontrolled growth in cancer.
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